Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.

Stanley Druckenmiller has made Natera his largest hedge fund position, betting on the company's disruptive blood-testing technology across prenatal screening, organ transplant monitoring, and cancer care. While Natera shows impressive 37.7% revenue growth and 1,000% growth over 10 years, the author argues the stock's P/S ratio of 21 is dangerously high compared to its long-term average, warning that following Druckenmiller at current valuations may not end well.